Vortioxetine: Independent Evidence on Depression, Cognition Claims, Side Effects
Vortioxetine (Brintellix/Trintellix) beats placebo modestly but is not proven better than older antidepressants; its cognitive claims rest on maker-funded trials.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Vortioxetine (Brintellix/Trintellix) beats placebo modestly but is not proven better than older antidepressants; its cognitive claims rest on maker-funded trials.
Venlafaxine (Effexor) works for depression and anxiety, but independent evidence flags blood pressure rises, hard withdrawal and higher overdose toxicity.
Trazodone is licensed for depression but mostly prescribed off-label for sleep. Independent evidence on benefits, falls, priapism, withdrawal and funding.
Pregabalin (Lyrica) helps a minority with nerve pain, focal epilepsy or GAD, but misuse, dependence and breathing risks with opioids made it a UK controlled drug.
Paroxetine (Seroxat/Paxil) helps adult depression and anxiety short term, but has hard withdrawal, pregnancy and tamoxifen warnings, and the Study 329 history.
Mirtazapine works for depression, but sedation and weight gain are common. Off-label use for insomnia rests on thin evidence. Who funded the trials?
Esketamine nasal spray (Spravato) for treatment-resistant depression: what the FDA files, NICE and independent re-analyses show about its benefit, risks and funding.
Duloxetine (Cymbalta) works for depression, anxiety and diabetic nerve pain, but gains are modest and liver, bleeding and withdrawal risks need care.
Diazepam (Valium) eases acute anxiety, seizures and alcohol withdrawal fast, but carries FDA boxed warnings on opioids and dependence. What independent evidence shows.
Bupropion (Zyban/Wellbutrin): what independent evidence shows for quitting smoking and depression, seizure risk, sexual side effects, and who funds the research.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.